{
    "title": "Gilead profit tops expectations despite lower COVID drug sales, outlook raised",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11362915/Gilead-profit-tops-expectations-despite-lower-COVID-drug-sales-shares-rise.html",
    "date": "2022-10-27",
    "keywords": [
        "drug",
        "gilead",
        "share",
        "cancer",
        "company",
        "demand",
        "treatment",
        "veklury",
        "beasley",
        "profit",
        "hiv",
        "forecast",
        "revenue",
        "street",
        "year",
        "business",
        "product",
        "trodelvy",
        "administration",
        "application",
        "thursday",
        "thirdquarter",
        "back",
        "acquisition",
        "average",
        "estimate",
        "remdesivir",
        "brand",
        "name",
        "youve",
        "performance",
        "base",
        "chief",
        "executive",
        "daniel",
        "income",
        "ceo",
        "rest",
        "world",
        "weve",
        "ball",
        "pandemic",
        "covid",
        "phase",
        "trial",
        "quarter",
        "cell",
        "oncology",
        "portfolio",
        "area",
        "growth",
        "analyst",
        "michael",
        "email",
        "food",
        "december",
        "lenacapavir",
        "filing",
        "use",
        "breast",
        "fda",
        "hepcludex",
        "hepatitis",
        "manufacturing",
        "outlook",
        "range",
        "guidance",
        "environment",
        "uncertainty",
        "macro",
        "nature",
        "biotech",
        "yee",
        "reporting",
        "deena",
        "bill",
        "berkrot",
        "deepa",
        "babington"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}